Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021.
Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond.
Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM). Race’s Managing Director and CEO, Mr Phil Lynch commented, “At the time we released our updated Three Pillar…
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology.
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. • Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00) • Race’s 5 Path Strategy | Dr Daniel Tillett CSO (10.00 – 39.00) • Conclusion…
